In the following video, Motley Fool healthcare analyst David Williamson takes a look at Eli Lilly's (LLY +4.57%) CEO, John Lechleiter, examining both how his background as a scientist makes him an a rarity in big pharma and highlighting his rise to the top of Eli Lilly. David then tells investors why Lechleiter's background is both a strength for the company -- and a potential weakness.
Is Eli Lilly's Management Charting the Right Course?
By Dave Williamson – Mar 24, 2013 at 9:00AM
NYSE: LLY
Eli Lilly
Market Cap
$914B
Today's Change
(4.57%) $42.27
Current Price
$966.64
Price as of November 10, 2025 at 4:00 PM ET
Is management at Eli Lilly an asset or a liability?
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid